Publicacións (392) Publicacións nas que participase algún/ha investigador/a

2024

  1. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

    Journal of Infectious Diseases, Vol. 229, pp. S112-S119

  2. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  3. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

  4. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. S18-S24

  5. External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children

    Archives of Disease in Childhood, Vol. 109, Núm. 1, pp. 58-66

  6. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  7. Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study

    The Lancet Child and Adolescent Health, Vol. 8, Núm. 5, pp. 325-338

  8. Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia

    Genes and Diseases, Vol. 11, Núm. 3

  9. Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

    Emerging Microbes and Infections

  10. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

    The Pediatric infectious disease journal, Vol. 43, Núm. 5, pp. 444-453

  11. Raising AWaRe-ness of Antimicrobial Stewardship Challenges in Pediatric Emergency Care: Results from the PERFORM Study Assessing Consistency and Appropriateness of Antibiotic Prescribing Across Europe

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 526-534

  12. Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 161-170

  13. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107

  14. Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study

    Journal of Infectious Diseases

  15. Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus

    Nature Communications, Vol. 15, Núm. 1

  16. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

    Nature communications, Vol. 15, Núm. 1, pp. 3083

  17. Which low urgent triaged febrile children are suitable for a fast track? An observational European study

    Emergency Medicine Journal, Vol. 41, Núm. 4, pp. 236-241

2023

  1. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

    Vaccine, Vol. 41, Núm. 21, pp. 3387-3398

  2. A multi-platform approach to identify a blood-based host protein signature for distinguishing between bacterial and viral infections in febrile children (PERFORM): a multi-cohort machine learning study

    The Lancet. Digital health, Vol. 5, Núm. 11, pp. e774-e785

  3. Addressing Determinants of Immunization Inequities Requires Objective Tools to Devise Local Solutions

    Vaccines